<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">38967104</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2125</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Jul</Month><Day>05</Day></PubDate></JournalIssue><Title>British journal of clinical pharmacology</Title><ISOAbbreviation>Br J Clin Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Authors' response to letter 'On the use of open-label studies for the evaluation of cannabis-based products for the treatment of long-COVID'.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/bcp.16174</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thurgur</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-7714-3446</Identifier><AffiliationInfo><Affiliation>Drug Science, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynskey</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Drug Science, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlag</LastName><ForeName>Anne Katrin</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Drug Science, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Croser</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Nutt</LastName><ForeName>David John</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-1286-1401</Identifier><AffiliationInfo><Affiliation>Drug Science, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iveson</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Stroke and Neurorehabilitation, Nuffield Health, York, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Clin Pharmacol</MedlineTA><NlmUniqueID>7503323</NlmUniqueID><ISSNLinking>0306-5251</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>5</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>5</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38967104</ArticleId><ArticleId IdType="doi">10.1111/bcp.16174</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>